



**FOR IMMEDIATE RELEASE**

## **Corindus to Present at 13<sup>th</sup> Annual Wells Fargo Securities Healthcare Conference**

**Waltham, MA – August 23, 2018** – Corindus Vascular Robotics, Inc. [NYSE American: CVRS], a leading developer of precision vascular robotics, announced today that Mark Toland, President and Chief Executive Officer, will present at the 13<sup>th</sup> Annual Wells Fargo Securities Healthcare Conference. Details for the presentation include:

Date	September 5, 2018
Time	3:35pm EDT
Location	The Westin Copley Place, Boston
Webcast	<a href="https://cc.talkpoint.com/well001/090518a_as/?entity=64_PFTDIHU">https://cc.talkpoint.com/well001/090518a_as/?entity=64_PFTDIHU</a>

The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the company's website at [investors.corindus.com](http://investors.corindus.com), under the News & Events Section.

### **About Corindus Vascular Robotics**

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique \$1,000 hospital credit "One Stent Program." For additional information, visit [www.corindus.com](http://www.corindus.com), and follow @CorindusInc.

###

#### **Media Contact:**

Corindus Vascular Robotics, Inc.  
Kate Drake  
T: (508) 653-3335 ext. 200  
[kate.drake@corindus.com](mailto:kate.drake@corindus.com)

#### **Investor Contact:**

Lisa Wilson  
In-Site Communications, Inc.  
T: 917-543-9932  
[ir@corindus.com](mailto:ir@corindus.com)